Plavix, other antiplatelets increase bleeding risk for kidney disease patients


People suffering from chronic kidney disease (CKD) are more likely to be harmed by antiplatelet drugs used to prevent cardiovascular disease, according to results from a recently published study.

Antiplatelet drugs like Plavix are often a preferred treatment in the prevention of cardiovascular disease but adding it as a treatment among patients suffering from CKD greatly increases the risk of severe and life-threatening bleeding events, according to researchers at University of Otago Christchurch in New Zealand who’ve published an analysis of clinical data on the use of antiplatelet drugs in Annals of Internal Medicine.

The urge to prescribe a drug like Plavix stems from the increased risk of cardiovascular disease faced by people with CKD. According to a report on the study posted at, “Patients with early-stage CKD have a 25 percent to 30 percent increased risk of developing cardiovascular disease (CVD) and that risk becomes more than 30- to 50-fold higher in patients with end-stage kidney disease.”

More and more people are suffering from CKD as rates of diabetes and obesity increase nationwide. Kidney diseases affect millions of Americans and the rate is expected to increase.

In some of the studies analyzed, the combination of an antiplatelet drug with treatments common for CKD was associated with at least six fatal strokes among just more than 400 patients. Overall, the combination of drugs like Plavix among patients suffering from a range of kidney diseases increased the risk of severe bleeding.